LONDON--(BUSINESS WIRE)--Technavio market research company announces their latest report on gene therapy for ovarian cancer 2018-2022. The market research report provides a detailed study for ovarian cancer along with the pipeline landscape. It consists of a comparative analysis and indication analysis. The report also lists out the major regulatory authorities in different geographies.
Gene therapy for ovarian cancer - market overview
Several types of cells within the ovary leads to ovarian cancer and has the lowest survival rate of all gynecological cancers. Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types.
The immunotherapy market for ovarian cancer has some commercially successful chemotherapy products. Chemotherapy is a combination of two or more drugs that is given after every 3-4 weeks and has a long-lasting aide/adverse effects. Studies have shown that chemotherapy can damage the blood-producing cells of bone marrow that results in blood related complications.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Save more with Technavio. Buy 2 reports and get the third for FREE: View all Technavio’s current offers
Gene therapy is expected to be one of the next big paradigm shift in pharmacology due to the extensive on-going research studies, both at academic and industry level.
According to a senior analyst at Technavio for oncology, “Gene therapy is one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy is gaining attention as it has the potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Gene therapy for ovarian cancer - segmentation analysis
The gene therapy for ovarian cancer is segmented on the basis of the type of ovarian cancer (ovarian cancer (unspecified), recurrent ovarian epithelial cancer, and platinum-resistant ovarian cancer) and RoA (intraperitoneal, intravenous, intratumoral, and unspecified).
The report also consists of companies that are actively involved in the development of gene therapy for ovarian cancer. Based on their financial status, the companies are segmented into Tier-1, Tier-2, and Tier-3.
|
Technavio’s best deals of the month!
Celebrate Earth Day and clean energy with Technavio. Get 30% discount on all Energy reports. Offer valid from 12th March - 18th March.
OR
Get 20% off on all Media and Entertainment Services reports. Offer valid only till the 31st of March. |
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
